Posted by Michael Wonder on 11 Mar 2024
ICER publishes final evidence report on treatment for schizophrenia
11 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits for KarXT compared to generically available aripiprazole; if long-term data confirm KarXT’s benefits and lack of weight gain, it would achieve common thresholds for cost-effectiveness if priced between $16,000 - $20,000/year.
The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of xanomeline tartrate/trospium chloride (KarXT, Karuna Therapeutics) for the treatment of schizophrenia.
